Global Blood Gas and Electrolyte Analyzers Market to Surpass USD 2 Billion by 2023
|
By LabMedica International staff writers Posted on 17 Aug 2021 |
|
Illustration
The global blood gas and electrolyte analyzers market was valued at USD 1.43 billion in 2016 and is projected to register a CAGR of 5.7% from 2017 to 2023 to reach USD 2.1 billion by 2023, driven by an increase in patients suffering from chronic diseases and improvement in healthcare facilities.
These are the latest findings of Allied Market Research (Portland, OR, USA), a market research and advisory company.
Blood gas analyzers are used to measure different parameters, such as pH, blood gas (pCO2 and pO2), electrolytes, and metabolites, from the whole blood samples. An increase in patients being treated in ICUs, NICUs, and emergency departments; rise in patients suffering from chronic diseases; technological advancement in blood gas & electrolyte analyzers, and increase in the number of product approvals are the major factors driving the market growth. However, complexities involved in the interpretation of data are restraining the market growth. Nevertheless, an increase in investment by major medical diagnostics giants and improvement in healthcare facilities in Asia-Pacific is providing growth opportunities for the global blood gas and electrolyte analyzers market.
Based on modality, the portable analyzer segment accounted for the highest share of the global blood gas & electrolyte analyzers market in 2016. On the basis of product/brand, the ABL Flex segment contributed the highest revenue to the global market in 2016. Based on end user, the hospitals segment holds the highest share in the global blood gas and electrolyte analyzers market, owing to the rise in number of patients treated in ICUs, NICUs, and emergency departments, where the utilization of blood gas analyzers is higher to treat patients in a critical condition.
Geographically, North America dominated the global blood gas and electrolyte analyzers market in 2016, and is estimated to maintain its dominance during the forecast period. This can be attributed to the higher adoption of technologically-advanced devices, well-equipped healthcare facilities, and rise in admission of patients in ICUs, NICUs, and emergency departments.
Related Links:
Allied Market Research
These are the latest findings of Allied Market Research (Portland, OR, USA), a market research and advisory company.
Blood gas analyzers are used to measure different parameters, such as pH, blood gas (pCO2 and pO2), electrolytes, and metabolites, from the whole blood samples. An increase in patients being treated in ICUs, NICUs, and emergency departments; rise in patients suffering from chronic diseases; technological advancement in blood gas & electrolyte analyzers, and increase in the number of product approvals are the major factors driving the market growth. However, complexities involved in the interpretation of data are restraining the market growth. Nevertheless, an increase in investment by major medical diagnostics giants and improvement in healthcare facilities in Asia-Pacific is providing growth opportunities for the global blood gas and electrolyte analyzers market.
Based on modality, the portable analyzer segment accounted for the highest share of the global blood gas & electrolyte analyzers market in 2016. On the basis of product/brand, the ABL Flex segment contributed the highest revenue to the global market in 2016. Based on end user, the hospitals segment holds the highest share in the global blood gas and electrolyte analyzers market, owing to the rise in number of patients treated in ICUs, NICUs, and emergency departments, where the utilization of blood gas analyzers is higher to treat patients in a critical condition.
Geographically, North America dominated the global blood gas and electrolyte analyzers market in 2016, and is estimated to maintain its dominance during the forecast period. This can be attributed to the higher adoption of technologically-advanced devices, well-equipped healthcare facilities, and rise in admission of patients in ICUs, NICUs, and emergency departments.
Related Links:
Allied Market Research
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Latest Industry News
- Partnership Brings Automated Pathology Archiving Solutions to U.S. Labs
- New Collaboration Integrates Low-Code Automation into Laboratory Platform
- LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
- Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
- Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Seed Amplification Test Expands Access to Neurodegenerative Disease Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more
Molecular Diagnostics
view channel
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read more
Hematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Pathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more